Centrum 7/6  banner

Aquestive Therapeutics

Aquestive Therapeutics announces FDA approval for Sympazan

Aquestive Therapeutics announces FDA approval for Sympazan

WARREN, N.J. – Aquestive Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved Sympazan (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Sympazan is the first and only oral film FDA-approved to treat seizures associated with LGS. Previously, clobazam was marketed as

PP_1170x120_10-25-21